(FLNA) Filana Therapeutics, Inc. Business Model Canvas Research

Manufacturing and analytical labs are core partners for Filana Therapeutics, Inc. because they make the active compound, run release tests, and confirm quality before clinical batches scale up. They also keep investigational materials consistent lot to lot, which is critical when small early-stage supplies must match later trial demand.

• Compound production support
• Release testing and QC checks
• Batch-to-batch consistency

Capital and licensing partners matter for Filana Therapeutics, Inc. because PTI-125 and PTI-125Dx need long, costly R&D, and biotech deals often bring non-dilutive cash, milestone payments, and access to data or trial networks. In 2025, early-stage biotech financing stayed selective, so partner capital can shorten the path to clinic and reduce equity dilution.

• Non-dilutive cash supports long trials
• Milestones fund later-stage work
• Licensing adds strategic access
• PTI-125 and PTI-125Dx are key assets

For Filana Therapeutics, Inc., regulatory and IP management is core to value creation: a U.S. patent usually lasts 20 years from filing, while a biologic can gain 12 years of FDA data exclusivity and 7 years for orphan drug exclusivity. Strong filings, clean study records, and fast patent moves help keep commercialization options open.

That means protecting the platform early, documenting every trial result, and aligning CMC and FDA/EMA plans before pivotal studies start.

• Protect patents early.
• Track study data tightly.
• Plan FDA and EMA filings.
• Preserve long-term launch rights.

Filana Therapeutics, Inc. must keep raising capital because development-stage biotech firms often fund each milestone with new equity, debt, or non-dilutive deals. Business development helps secure partnerships, licensing, and strategic financing, which can cut cash burn and keep the pipeline moving; many pre-revenue biotechs still face 12-24 month funding cycles.

• Raise capital to fund trials
• Win partners for co-development
• License assets for cash upfront
• Use financing to extend runway

Founded by Remi Barbier in May 1998, Filana Therapeutics brings 28 years of founder-led continuity into a long biotech cycle. That kind of tenure can support investor confidence, while seasoned leadership matters when programs can take 5-10+ years from discovery to clinic and carry high capital risk.

• Founder-led since May 1998
• 28 years of continuity in 2026
• Supports long-cycle biotech execution

Filana Therapeutics, Inc. keeps its principal office in Austin, Texas, giving the company one fixed base for administration, coordination, and corporate governance. The Austin hub also anchors its operating presence in a 0 state-income-tax jurisdiction, which can support leaner central overhead.

• Austin office supports daily control
• Centralizes governance and coordination
• Anchors U.S. operating presence

Filana Therapeutics, Inc. runs a single-company platform with 2 linked programs: treatment and diagnostics. One team can align science faster, cut duplicate work, and make partner talks simpler, while shared data can create cross-program synergies.

• 1 company, 2 programs
• Faster scientific coordination
• Cleaner partner discussions
• Shared data can lift value

Founded in 1998, Filana Therapeutics, Inc. signals rare persistence in Alzheimer’s R&D, where the median clinical development timeline often runs 10-15 years and over 95% of candidates fail before approval. That long runway can strengthen credibility because continuity matters when progress depends on steady trial design, data, and capital.

• Founded in 1998
• Long-horizon Alzheimer’s work
• Credibility through continuity

Trial participant support in Filana Therapeutics, Inc. must keep patients and caregivers informed, since Alzheimer’s studies often need repeated visits, cognitive testing, and tight protocol compliance. Clear help can improve recruitment, retention, and data quality, and in dementia trials even small dropout cuts matter because each missed visit weakens endpoint power.

• Boosts recruitment and retention
• Supports caregivers, not just patients
• Improves visit and drug compliance

Licensing partner management at Filana Therapeutics, Inc. depends on tight milestone tracking, shared technical reviews, and clear business terms, since every partner deal can shape the path to commercialization. In biotech, licensing partnerships often hinge on value creation at each stage, and McKinsey has said up to 80% of value can be decided in the first 3 years after launch.

• Structured updates reduce deal drift
• Technical reviews protect development quality
• Milestones keep commercialization on track

Filana Therapeutics, Inc. uses its corporate website and media releases as public-facing channels for company news, pipeline updates, and investor access. They support awareness, recruiting, and stakeholder trust at low cost because one release can reach thousands of readers without a sales team.

• Public news and pipeline updates
• Supports hiring and outreach
• Low-cost, scalable messaging

Business development outreach is Filana Therapeutics, Inc.'s direct path to licensing and strategic alliances, aimed at companies that can fund, co-develop, or commercialize assets. For pre-revenue biotech, this channel matters because one successful partner can bring upfront cash, milestones, and shared risk; recent biopharma deals often include upfront payments in the millions and total deal values above $1 billion.

• Targets funding and commercial partners
• Supports licensing and co-development
• Reduces risk before revenue starts

Hospitals and diagnostic labs are key users because they can embed Filana Therapeutics, Inc. diagnostic tools into daily clinical workflows. They need reliable test performance, clear SOPs, and smooth IT and lab fit, since U.S. labs run billions of tests each year and small workflow breaks can slow adoption.

• Reliable results
• Clear protocols
• Easy workflow fit

These buyers matter for scale: once a test fits hospital and lab operations, it can move from pilot use to recurring volume across large health systems.

Pharma and research partners can license, co-develop, or fund Filana Therapeutics, Inc. programs, which matters in pre-commercial biotech where capital gaps are common. In 2025, global pharma R&D spending stayed above $250 billion, so partners pay for differentiated assets with clear clinical signals and de-risked data, not just early science.

• License, co-develop, or fund programs
• Need strong clinical evidence
• Prefer differentiated assets

Patent filings, freedom-to-operate counsel, and compliance work are fixed pharma costs, and they rise fast as a program moves toward IND and FDA review. Industry data still points to heavy spend: one drug can take 10-15 years and about $2.6 billion to develop, so regulatory planning is not optional for Filana Therapeutics, Inc.

• Protect IP early.
• Budget for FDA planning.
• Expect millions in legal spend.

General and administrative overhead at Filana Therapeutics, Inc. covers the Austin office, admin support, finance, reporting, and governance. This cost layer keeps the company running between R&D milestones, and because Filana Therapeutics, Inc. has not publicly filed 2025/2026 overhead figures, the clean read is structural, not numeric.

• Austin office and admin support
• Finance, reporting, governance
• Keeps operations active between milestones

Research grants can fund Filana Therapeutics, Inc.'s early science without dilution, especially for disease research or diagnostic work. In FY2025, NIH SBIR grants capped at $326,687 for Phase I and $2,178,936 for Phase II, so this stream can ease cash burn and reduce financing pressure.

• Non-dilutive capital
• Disease and diagnostic focus
• Lower equity dilution

If approved, Filana Therapeutics, Inc. could earn direct sales from therapeutics and diagnostics, while partner deals could add royalties, often in the 5%-15% range of net sales. These streams are the long-term upside because they scale with launches, not just research spend.

• Direct sales need regulatory approval
• Royalties can add margin light income
• Upside grows with each commercial hit